Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration

Expert Opinion on Drug Delivery

Volumn 4, Issue 4, 2007, Pages 427-440

  Frost, Gregory I ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

Hyaluronan; Hyaluronic acid; Hylenex; Hyluronidase; rHuPH20

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPIVACAINE; CONTRAST MEDIUM; CYTOTOXIC AGENT; GLYCOSAMINOGLYCAN; HYALURONIDASE; HYLENEX; LIDOCAINE; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT DNA; RECOMBINANT HUMAN HYALURONIDASE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANESTHESIA; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; EXTRACELLULAR MATRIX; GENETIC ENGINEERING; GENOME; HUMAN; KIDNEY TUBULE DISORDER; MULTIGENE FAMILY; NONHUMAN; SUBCUTANEOUS TISSUE;

AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION MOLECULES; DERMIS; EXTRACELLULAR MATRIX; HUMANS; HYALURONOGLUCOSAMINIDASE; INJECTIONS, SUBCUTANEOUS; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SOLUBILITY;

EID: 34547893864     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.4.427     Document Type: Article

References (76)

1. SUPERSAXO A, HEIN WR, STEFFEN H: Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. (1990) 7:167-179.
2. DAY TD: The permeability of extracellular connective tissue and the nature of the interfibrillary substance. J. Physiol. (1952) 17:1-8.
3. TAYLOR AE, GRANGER DN: Exchange of macromolecules across the microcirculation. In: Handbook of Physiology. The Cardiovascular System. Microcirculation. Bethesda, MD: Am. Physiol. Soc. (1984) 4:467-520.
4. REED RK: Extracellular-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. (1993) 73:1-78.
5. REED RK, LEPSOE S, WIIG H: Interstitial exclusion of albumin in rat dermis and subcutis in over- and dehydration. Am. J. Physiol. (1989) 257:1819-1827.
6. CRAIG AS, EIKENBERRY EF, PARRY DAD: Ultrastructural organization of skin: classification on the basis of mechanical role. Connect. Tissue Res. (1987) 16:213-223.
7. VERZIJL N, DEGROOT J, THORPE SR et al.: Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol. Chem. (2000) 275:39027-39031.
8. LAURENT UBG, DAHL LB, REED RK: Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver. Exp. Physiol. (1991) 76:695-703.
9. FRASER JR, LAURENT TC:. Ciba Found Symp. (1989) 143:41-53; discussion 53-59, 281-285.
10. STARLING EH: On the absorption of fluids from the convective tissue spaces. J. Physiol. (1896) 19:312-326.
11. PORTER CJ, CHARMAN SA: Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. (2000) 89:297-310.
12. FATOUROS A, LIDEN Y, SJOSTROM B: Recombinant factor VIII SQ-stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue. J. Pharm. Pharmacol. (2000) 52:797-805.
13. MCMINN RMH (Ed.), Last's Anatomy: Regional and applied (9th Edition). London: Churchill Livingstone (1994).
14. ROSE EH, VISTNES LM, KSANDER GA: The pannicu]us carnosus in the domestic pig. Plast Reconst. Surg. (1977) 59:94-97.
15. THE ZITIER GROUP: The managed care injectables index: spring (2005).
16. NUIJTEN MJ, ENGELFRIET P, DUIJN K, BRUIJN G, WIERZ D, KOOPMANSCHAP M: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics (2001) 19:1051-1064.
17. GARDULF A, NICOLAY U: Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr: Opin. Allergy Clin. Immunol. (2006) 6:434-442.
18. LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous ants-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768-773.
19. LAURENT UBG, DAHL LB, REED RK: Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver. Exp. Physiol. (1991) 76:695-703.
20. DURAN REYNALS F: Exaltation de l'activité du virus vaccinal par les extraits de certains organes. Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie (1928) 99:6-7.
21. CLAUDE A, DURAN-REYNALS F: Chemical properties of the purified spreading factor from testicle. J. Exp. Med. (1937) 65:661-670.
22. DURAN-REYNALS F: Further studies on the influence of testicle extract upon the effect of toxins, bacteria, and Viruses, and on the Shwartzman and Arthus phenomena. J. Exp. Med. (1933) 58:451-463.
23. DURAN-REYNALS F: A spreading factor in certain snake venoms and tts relation to their mode of action J. Exp. Med. (1939) 69:69-81.
24. DUTHIE ES, CHAIN EA: A mucolytic enzyme in testes extracts. Nature (1939) 144:977-978.
25. MEYER K, Hyaluronidases, In: Boyer PD (Ed.), The Enzymes. Academic Press, New York. (1971):307-320.
26. MEYER K, RAPPORT MM: Hyaluronidases. Adv. Enzymol. Relat. Subj. Biochem. (1952) 13:199-236.
27. MEYER K, HOFFMAN P, LINKER A: Hyaluronidases. In: Boyer PD, Lardy H, Myrbäck K (Eds), The Enzymes, 2nd Edition, Volume 4, Academic Press, New York (1960):447-460.
28. RAPPORT MM, MYER K, LINKER A: Analysis of the products formed on hydrolysis of hyaluronic acid by testicular hyaluronidase. J. Am. Chem. Soc. (1951) 73:2416-2420.
29. HARRISON RA, GAUNT SJ: Multiple forms of ram and bull sperm hyaluronidase revealed by using monoclonal antibodies. J. Reprod. Fertil. (1988) 82:777-785.
30. HARRISON RA: Hyaluronidase in ram semen. Quantitative determination, and isolation of multiple forms. Biochem. J. (1988) 252:865-874.
31. BORDERS CL, RAFTERY MA: Purification and partial characterization of testicular hyaluronidase. J. Biol. Chem. (1968) 243:3756-37562.
32. LATHROP WF, CARMICHAEL EP, MYLES DG, PRIMAKOFF P: cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals. J. Cell Biol. (1990) 111:2939-2949.
33. GMACHL M, KREIL G: Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm. Proc. Natl. Acad. Sci. USA (1993) 90:3569-3573.
34. GMACHL M, SAGAN S, KETTER S, KREIL G: The human sperm protein PH-20 has hyaluronidase activity. FEBS Lett. (1993) 336:545-548.
35. CSOKA AB, FROST GI, STERN R: The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. (2001) 20:499-508.
36. FROST GI, CSOKA AB, WONG T, STERN R: Purification, cloning, and expression of human plasma hyaluronidase. Biochem. Biophys. Res. Commun. (1997) 236:10-15.
37. CHERR GN, MEYERS SA, YUDIN AI et al.: The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity. Dev. Biol. (1996) 175:142-153.
38. GACESA P, CIVILL ND, HARRISON RA: PH-20 and sperm hyaluronidase: a conceptual conundrum in mammalian fertilization. Biochem. J. (1994) 303:335-336.
39. MEYER MF, KREIL G, ASCHAUER H: The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme. FEBS. Lett. (1997) 413:385-388.
40. ARMING S, STROBL B, WECHSELBERGER C, KREIL G: In vitro mutagenesis of PH-20 hyaluronidase from human sperm. Eur. J. Biochem. (1997) 247:810-814.
41. FROST GI, STERN R: A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. Anal. Biochem. (1997) 251:263-269.
42. KEISER HD, HATCHER YB: The effect of contaminant proteases in testicular hyaluronidase preparations on the immunological properties of bovine nasal cartilage proteoglycan. Connect. Tissue Res. (1979) 6:229-233.
43. DOCTOR VM, SPENCE H, CARROLL EY: Isolation and properties of a new anticoagulant protein from commercial bovine testicular hyaluronidase. Thromb. Res. (1883) 30:565-571.
44. HYUGA M, KODAMA R, EGUCHI G: Basic fibroblast growth factor as one of the essential factors regulating lens transdifferentiation of pigmented epithelial cells. Int. J. Dev. Biol. (1993) 37:319-326.
45. HOUCK JC, CHANG CM: Permeability factor contaminating hyaluronidase preparations. Inflammation (1979) 4:447-451.
46. OETTL M, HOECHSTETTER J, ASEN I, BERNHARDT BUSCHAUER GA: Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from Streptococcus agalactiae in pharmaceutical preparations. Eur. J. Pharm. Sci. (2003) 18:267-277.
47. BOOKBINDER LH, HOFER A, HALLER MF et al.: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release (2006) 114:230-241.
48. HECHTER O: Studies on spreading factors: I. The importance of mechanical factors in hyaluronidase action in skin. J. Exp. Med. (1947) 85:77-97.
49. FESSLER JH: Mode of action of testicular hyaluronidase. Biochem. J. (1960) 76:132-135.
50. HECHTER O, DOPKEEN SK, YUDELL MH: The clinical use of hyaluronidase in hypodermoclysis. J. Peds. (1947) 30:645-656.
51. LINSENMAYER TF: Collagen. In: Cell Biology of Extracellular Matrix. Hay ED (Ed.), New York: Plenum (1981):5-37.
52. WOLF RA, CHAUNG LY, O'HARA D, SMITH TW, MULLER JE: The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans. J. Pharmacol. Exp. Ther. (1982) 222:331-337.
53. TAMMI R, SAAMANEN AM, MAIBACH HI, TAMMI M: J. Invest. Dermatol. (1991) 97:126-130.
54. LAURENT TC, FRASER JRE: In: Degradation of Bioactive Substances: Physiology and Pathophysiology. Henriksen JH (Ed.), CRC Press, Boca Raton, FL (1991):249-265.
55. HARRIS EN, WEIGEL JA, WEIGEL PH: Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. (2004) 279:36201-36209.
56. HECHTER O: Reconstitution of the dermal barrier to fluid diffusion following administration of hyaluronidase. Proc. Soc. Exp. Biol. Med. (1948) 67:343-344.
57. MUCKENSCHNABEL I, BERNHARDT G, SPRUSS T, BUSCHAUER A. Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy. Cancer Lett. (1998) 131(1):71-84.
58. FEDERAL REGISTER Volume 35 (1970):14800-14801.
59. JAWORSKI A, FARLEY JE Jr: Hyaluronidase in administration of fluids. Am. J. Dis. Child. (1950) 79:59-64.
60. BURKET EC, GYÖRGY P: Clinical observations on the use of hyaluronidase. Pediatrics (1949) 3:56-63.
61. ATKINSON WS: Use of hyaluronidase with local anesthesia in ophthalmology; preliminary report. Arch. Ophthal. (1949) 42:628-633.
62. TASSMAN IS: The use of hyaluronidase in ophthalmology. Am. J. Ophthalmol. (1952) 35:683-686.
63. ALWITRY A, CHAUDHARY S, GOPEE K, BUTLER TK, HOLDEN R: Effect of hyaluronidase on ocular motility in sub-Tenon's anesthesia: randomized controlled trial. J. Cataract Refract. Surg. (2002) 8:11420-1423.
64. KALLIO H, PALOHEIMO M, MAUNUKSELA EL: Hya]uronidase as an adjuvant in bupivacaine-lidocaine mixture for retrobulbar/peribulbar block. Anesth. Analg. (2000) 91:934-937.
65. JEHAN FS, HAGAN JC III, WHITTAKER TJ, SUBRAMANIAN M: Diplopia and ptosis following injection of local anesthesia without hyaluronidase. J. Cataract Refract. Surg. (2001) 11:1876-1879.
66. HAMADA S, DEVYS JM, XUAN TH et al.: Role of hyaluronidase in diplopia after peribulbar anesthesia for cataract surgery. Ophthalmology (2005) 112:879-882.
67. INTRAVENOUS NURSES SOCIETY: Infiltration/Extravasation. J. Intravenous Nursing (1998) 21(1S):S36-S37.
68. GOOLSBY TV, LOMBARDO FA: Extravasation of chemotherapeutic agents: prevention and treatment. Semin. Oncol. (2006) 33:139-143 (Review).
69. BERTELLI G, DINI D, FORNO GB et al.: Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res. Clin. Oncol. (1994) 120:505-506.
70. LAURIE SWS, WILSON KL, KERNAHAN DA, BAUER DS, VISTNES LM: Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann. Plastic Surg. (1984) 13:192-194.
71. DORR RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev. (1990) 4:41-60.
72. RASZKA WV Jr, KUESER TK, SMITH FR, BASS JW: The use of hyaluronidase in the treatment of intravenous extravasation injuries. J. Perinatol. (1990) 10:146-149.
73. KUMAR MM, SPRUNG J: The use of hyaluronidase to treat mannitol extravasation. Anesth. Analg. (2003) 97: 1199-2000.
74. ZENK KE, DUNGY CI, GREENE GR: Nafcillin extravasation injury. Use of hyaluronidase as an antidote. Am. J. Dis. Child. (1981) 135:1113-1114.
75. COCHRAN ST, BOMYEA K, KAHN M: Treatment of iodinated contrast material extravasation with hyaluronidase. Acad. Radio. (2002):S544-S546.
76. SIMON NL, NARIN L: The effect of hyaluronidase on the absorption of a subcutaneously deposited radiopaque substance. Amer. J. Roentgen. (1949) 61:91-94.